Current available therapies and future directions in the treatment of malignant gliomas

References

• Cancer Facts and Figures 2005Surveillance ResearchAmerican Cancer Society IncAtlanta, USA2005160
   Google Scholar
• Statistical Report: Primary Brain Tumors in the United States, 1997–2001Central Brain Tumor Registry of the United StatesHinsdaleUSA2004
   Google Scholar
• KleihuesPCaveneeWKPathology and genetics: Tumors of the nervous systemWorld Health Classification of tumorsInternational Agency for Research on CancerAlbany, USA2000314
   Google Scholar
• LouisDNOhgakiHWiestlerODThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol (Berl)200711429710917618441
   PubMed Web of Science ®Google Scholar
• ScottCBScarantinoCUrtasunRValidation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90–06Int J Radiat Oncol Biol Phys199840151559422557
   PubMed Web of Science ®Google Scholar
• WongETHessKRGleasonMJOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsJ Clin Oncol19991782572257810561324
   PubMed Web of Science ®Google Scholar
• StewartLAChemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trialsLancet200235993111011101811937180
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• GersonSLMGMT: its role in cancer aetiology and cancer therapeuticsNat Rev Cancer20044429630715057289
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensACGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100315758010
   PubMed Web of Science ®Google Scholar
• FriedmanHSCan O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic?Clin Cancer Res2000682967296810955771
   PubMed Web of Science ®Google Scholar
• QuinnJADesjardinsAWeingartJPhase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJ Clin Oncol200523287178718716192602
   PubMed Web of Science ®Google Scholar
• KleihuesPCaveneeWKPathology and Genetics Tumours of the Nervous SystemIARC PressLyon2000314
   Google Scholar
• ReijneveldJCVoestEETaphoornMJAngiogenesis in malignant primary and metastatic brain tumorsJ Neurol200024759760811041327
   PubMed Web of Science ®Google Scholar
• ChaudhryLHO’DonovanDGBrenchleyPEReidHRobertsISVascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomasHistopathology20013940941511683943
   PubMed Web of Science ®Google Scholar
• KeLDShiYXImSAChenXYungWKThe relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity I human glioma cell linesClin Cancer Res200062562257210873113
   PubMed Web of Science ®Google Scholar
• PlateKHBreierGWeichHARisauWVascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivoNature19923598458481279432
   PubMed Web of Science ®Google Scholar
• SamotoKIkezakiKOnoMExpression of vascular endothelial growth factor and its possible relation with neovascualarization in human brain tumorsCancer Res199555118911937532545
   PubMed Web of Science ®Google Scholar
• LongoRSarmientoRFanelliMCapaccettiBGattusoDGaspariniGAnti-angiogenic therapy: Rationale, challenges and clinical studiesAngiogenesis2002523725612906317
   PubMedGoogle Scholar
• KimKJLiBWinerJInhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature19933628418447683111
   PubMed Web of Science ®Google Scholar
• PrestaLGChenHO’ConnorSJHumanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res199757459345999377574
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJGerberHNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Rev Drug Discov2004339140015136787
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerN Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel carboplatin alone or with bevacizumab for non-small cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJEPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res20071341253125917317837
   PubMed Web of Science ®Google Scholar
• VredenburghJDesjardinsAHerndonJEBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol2007254722472917947719
   PubMed Web of Science ®Google Scholar
• DesjardinsAReardonDAHerndonJE2ndBevacizumab plus irinotecan in recurrent WHO grade III malignant gliomasClin Cancer Res2008147068707318981004
   PubMed Web of Science ®Google Scholar
• CloughesyTFPradosMDWenPYA phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)J Clin Oncol200826May 20 suppl abstr 2010b
   Google Scholar
• GengLDonnellyEMcMahonGInhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapyCancer Res20016162413241911289107
   PubMed Web of Science ®Google Scholar
• KozinSVBoucherYHicklinDJBohlenPJainRKSuitHDVascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenograftsCancer Res2001611394411196192
   PubMed Web of Science ®Google Scholar
• LaiAFilkaEMcGibbonBNghiemphuPLPhase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityInt J Radiat Oncol Biol Phys20087151372138018355978
   PubMed Web of Science ®Google Scholar
• BatchelorTTSorensenAGdi TomasoEAZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell2007111839517222792
   PubMed Web of Science ®Google Scholar
• SaishinYSaishinYTakahasiKVEGF-TRAP R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrierJ Cell Physiol200319524124812652651
   PubMed Web of Science ®Google Scholar
• KonnerJDupontJUse of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activityClin Colorectal Cancer20044 Suppl 2S818515479484
   PubMedGoogle Scholar
• HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• WachsbergerPRBurdRCardiCVEGF trap in combination with radiotherapy improves tumor control in u87 glioblastomaInt J Radiat Oncol Biol Phys20076751526153717234361
   PubMed Web of Science ®Google Scholar
• De GrootJFWenPYLambornKPhase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601J Clin Oncol200826May 20 suppl abstr 2020
   Google Scholar
• GoldbrunnerRHBendszusMWoodJKiderlenMSasakiMTonnJCPTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularizationNeurosurgery2004552426432 discussion 43215271251
   PubMed Web of Science ®Google Scholar
• YungWKAFriedmanHConradCA phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiformeProceedings of the American Society of Clinical Oncology MeetingChicago, USA2003 Abstract 395
   Google Scholar
• ConradCFriedmanHReardonDA Phase I/II trial of single-agent PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)Proceedings of the American Society of Clinical Oncology MeetingNew Orleans, USA2004 Abstract 1512
   Google Scholar
• ReardonDFriedmanHYungWKAA phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)Proceedings of the American Society of Clinical Oncology MeetingNew Orleans, USA2004 Abstract 1513
   Google Scholar
• EkstrandAJJamesCDCaveneeWKSeligerBPetterssonRFCollinsVPGenes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivoCancer Res1991518216421722009534
   PubMed Web of Science ®Google Scholar
• PelloskiCEZhangLLinEEGFRvIII status defines distinct subtypes of glioblastoma: an analysis of 649 casesProceedings of the Eleventh Annual Meeting of the Society for Neuro-OncologyOrlando, USA2006 Abstract PA-26
   Google Scholar
• RichJNReardonDAPeeryTPhase II trial of gefitinib in recurrent glioblastomaJ Clin Oncol200422113314214638850
   PubMed Web of Science ®Google Scholar
• UhmJHBallmanKVGianniniCPhase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytomaProceedings of the American Society of Clinical Oncology MeetingNew Orleans, USA2004 Abstract 1505
   Google Scholar
• LiebermanFSCloughesyTFineHNABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomasProceedings of the American Society of Clinical Oncology MeetingNew Orleans USA2004 Abstract 1510
   Google Scholar
• PradosMDLambornKRChangSPhase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant gliomaNeuro Oncol200681677816443950
   PubMed Web of Science ®Google Scholar
• VogelbaumMAPeereboomDStevensGBarnettGBrewerCPhase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma mutliforme: Interim resultsProceedings of the American Society of Clinical Oncology MeetingNew Orleans, USA2004 Abstract 1558
   Google Scholar
• RaizerJJAbreyLEWenPA phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDsProceedings of the American Society of Clinical Oncology MeetingNew Orleans, USA2004 Abstract 1502
   Google Scholar
• MellinghoffIKWangMYVivancoIMolecular determinants of the response of glioblastomas to EGFR kinase inhibitorsN Engl J Med2005353192012202416282176
   PubMed Web of Science ®Google Scholar
• Haas-KoganDAPradosMDTihanTEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinibJ Natl Cancer Inst2005971288088715956649
   PubMed Web of Science ®Google Scholar
• KilicTAlbertaJAZdunekPRIntracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine classCancer Res200060185143515011016641
   PubMed Web of Science ®Google Scholar
• GengLShinoharaETKimDSTI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastomaInt J Radiat Oncol Biol Phys200664126327116274936
   PubMed Web of Science ®Google Scholar
• WenPYYungWKLambornKRPhase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08Clin Cancer Res200612164899490716914578
   PubMed Web of Science ®Google Scholar
• DresemannGImatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient seriesAnn Oncol200516101702170816033874
   PubMed Web of Science ®Google Scholar
• ReardonDAEgorinMJQuinnJAPhase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiformeJ Clin Oncol200523369359936816361636
   PubMed Web of Science ®Google Scholar
• DesjardinsAQuinnJAVredenburghJJPhase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomasJ Neurooncol2007831536017245623
   PubMed Web of Science ®Google Scholar
• KnobbeCBReifenbergerJReifenbergerGMutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomasActa Neuropathol (Berl)200410846747015517309
   PubMed Web of Science ®Google Scholar
• ShawRJCantleyLCRas, PI(3)K and mTOR signalling controls tumour cell growthNature200644142443016724053
   PubMed Web of Science ®Google Scholar
• CloughesyTFWenPYRobinsHIPhase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyJ Clin Oncol200624223651365616877733
   PubMed Web of Science ®Google Scholar
• GilbertMRGauppPLiuVA phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastomaProceedings of the American Society of Clinical Oncology MeetingAtlanta, USA2006 Abstract 1556
   Google Scholar
• SathornsumeteeSHjelmelandABKeirSTAAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant gliomaCancer Res200666178722873016951188
   PubMed Web of Science ®Google Scholar
• ChakravartiAZhaiGSuzukiYThe prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomasJ Clin Oncol2004221926193315143086
   PubMed Web of Science ®Google Scholar
• MomotaHNerioEHollandECPerifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivoCancer Res2005657429743516103096
   PubMed Web of Science ®Google Scholar
• LassmanAHollandEDeAngelisLPanageasKAbreyLClinical and molecular-metabolic phase II trial of perifosine for recurrent/progressive malignant gliomaNeuro Oncol200794467602 Abstract MA-15
   Web of Science ®Google Scholar
• ChangSMWenPCloughesyTPhase II study of CCI-779 in patients with recurrent glioblastoma multiformeInvest New Drugs20052335736116012795
   PubMed Web of Science ®Google Scholar
• GalanisEBucknerJCMaurerMJPhase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group StudyJ Clin Oncol2005235294530415998902
   PubMed Web of Science ®Google Scholar
• SawyersCLWill kinase inhibitors have a dark side?N Engl J Med200635531331516855275
   PubMed Web of Science ®Google Scholar
• FanQWKnightZAGoldenbergDDA dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell2006934134916697955
   PubMed Web of Science ®Google Scholar
• HuiAMZhangWChenWAgents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cellsCancer Res200464249115912315604281
   PubMed Web of Science ®Google Scholar
• BrandesAAErmaniMTurazziSProcarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II studyJ Clin Oncol199717264565010080610
   PubMed Web of Science ®Google Scholar
• SpenceAMPetersonRAScharnhorstJDSilbergeldDLRostomilyRCPhase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomasJ Neurooncol2004701919515527114
   PubMed Web of Science ®Google Scholar
• RobinsHIWonMSeiferheldWFPhase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021Neuro Oncol200681475216443947
   PubMed Web of Science ®Google Scholar
• TangPRoldanGBrasherPMA phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant gliomaJ Neuro Oncol2006783311316
   Web of Science ®Google Scholar
• PuchnerMJHerrmannHDBergerJCristanteLSurgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patientsJ Neurooncol200049214715511206010
   PubMed Web of Science ®Google Scholar
• ChangSMBarkerFG2ndHuhnSLHigh dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent gliomaJ Neurooncol19983721691769524096
   PubMed Web of Science ®Google Scholar
• CouldwellWTWeissMHDeGiorgioCMClinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifenNeurosurgery1993323485489 discussion 489–4908384328
   PubMed Web of Science ®Google Scholar
• GraffJRMcNultyAMHannaKRThe protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenograftsCancer Res200565167462746916103100
   PubMed Web of Science ®Google Scholar
• FineHAKimLRoyceCResults from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomasProceedings of the American Society of Clinical Oncology MeetingOrlando, USA2004 Abstract 1504
   Google Scholar
• FineHAPuduvalliVKChamberlainMCEnzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III studyJ Clin Oncol200826May 20 suppl abstr 2005
   Google Scholar
• BelloLFrancoliniMMarthynPZhangJCarrollRSNikasDCAlpha(v)beta3 and alpha(v)beta5integrin expression in glioma peripheryNeurosurgery2001492380389 discussion 39011504114
   PubMed Web of Science ®Google Scholar
• GingrasMCRousselEBrunerJMBranchCDMoserRPComparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissueJ Neuroimmunol1995571–21431537535788
   PubMed Web of Science ®Google Scholar
• GladsonCLExpression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumorsJ Neuropathol Exp Neurol19965511114311498939197
   PubMed Web of Science ®Google Scholar
• TuckerGCIntegrins: molecular targets in cancer therapyCurr Oncol Rep2006829610316507218
   PubMedGoogle Scholar
• NaborsLBMikkelsenTRosenfeldSSHochbergFAkellaNSFisherJDPhase I and correlative biology study of cilengitide in patients with recurrent malignant gliomaJ Clin Oncol200725131651165717470857
   PubMed Web of Science ®Google Scholar
• ReardonDAFinkKNaborsLBCloughesyTPlotkinSSchiffDGrunbergSMPhase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-00943rd Annual Meeting of American Society of Clinical OncologyChicago, ILLisa Greaves200775s
   Google Scholar
• StuppRGoldbrunnerRNeynsBPhase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM)J Clin Oncol 2007 ASCO Annual Meeting Proceedings200725Pt 1 No. 18S (June 20 Supplement)
   Google Scholar
• GoudarRKShiQHjelmelandMDCombination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibitionMol Cancer Ther20054110111215657358
   PubMed Web of Science ®Google Scholar
• RichJNSathornsumeteeSKeirSTZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumorsClin Cancer Res200511228145815716299247
   PubMed Web of Science ®Google Scholar
• SchuenemanAJHimmelfarbEGengLSU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor modelsCancer Res200363144009401612873999
   PubMed Web of Science ®Google Scholar
• SathornsumeteeSReardonDAQuinnJAAn update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant gliomaProceedings of the American Society of Clinical Oncology MeetingAtlanta, USA2006 Abstract 1560
   Google Scholar
• PradosMYungWWenPPhase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor ConsortiumProceedings of the American Society of Clinical Oncology MeetingNew Orleans, USA2004 Abstract 1504
   Google Scholar
• KrishnanSBrownPDBallmanKVPhase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177Int J Radiat Oncol Biol Phys20066541192119916626884
   PubMed Web of Science ®Google Scholar
• DelmasCHeliezCCohen-JonathanEFarnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiationInt J Cancer20021001434812115585
   PubMed Web of Science ®Google Scholar
• EshlemanJSCarlsonBLMladekACKastnerBDShideKLSarkariaJNInhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapyCancer Res200262247291729712499272
   PubMed Web of Science ®Google Scholar
• GasparLEFisherBJMacdonaldDRSupratentorial malignant glioma: patterns of recurrence and implications for external beam local treatmentInt J Radiat Oncol Biol Phys199224155571512163
   PubMed Web of Science ®Google Scholar
• HochbergFHPruittAAssumptions in the radiotherapy of glioblastomaNeurology19803099079116252514
   PubMed Web of Science ®Google Scholar
• BremHTamargoRJOliviABiodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brainJ Neurosurg19948022832908283268
   PubMed Web of Science ®Google Scholar
• BremHPiantadosiSBurgerPCPlacebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment GroupLancet19953458956100810127723496
   PubMed Web of Science ®Google Scholar
• WestphalMHiltDCBorteyEA phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomaNeuro Oncol200352798812672279
   PubMed Web of Science ®Google Scholar
• SouhamiLSeiferheldWBrachmanDRandomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocolInt J Radiat Oncol Biol Phys200460385386015465203
   PubMed Web of Science ®Google Scholar
• ShrieveDCAlexanderE3rdWenPYComparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiformeNeurosurgery1995362275282 discussion 282–2747731507
   PubMed Web of Science ®Google Scholar
• SelkerRGShapiroWRBurgerPThe Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustineNeurosurgery2002512343355 discussion 355–34712182772
   PubMed Web of Science ®Google Scholar
• LaperriereNJLeungPMMcKenzieSRandomized study of brachytherapy in the initial management of patients with malignant astrocytomaInt J Radiat Oncol Biol Phys1998415100510119719109
   PubMed Web of Science ®Google Scholar
• GabayanAJGreenSBSananAGliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysisNeurosurgery2006584701709 discussion 701–70916575334
   PubMed Web of Science ®Google Scholar
• CokgorIAkabaniGKuanCTPhase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomasJ Clin Oncol200018223862387211078500
   PubMed Web of Science ®Google Scholar
• ReardonDAAkabaniGColemanREPhase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasJ Clin Oncol20022051389139711870184
   PubMed Web of Science ®Google Scholar
• ReardonDAAkabaniGColemanRESalvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsJ Clin Oncol200624111512216382120
   PubMed Web of Science ®Google Scholar
• JainRKDelivery of molecular and cellular medicine to solid tumorsAdv Drug Deliv Rev2001461–314916811259838
   PubMed Web of Science ®Google Scholar
• BoboRHLaskeDWAkbasakAMorrisonPFDedrickRLOldfieldEHConvection-enhanced delivery of macromolecules in the brainProc Natl Acad Sci U S A1994916207620808134351
   PubMed Web of Science ®Google Scholar
• PradosMKunwarSLangFFFinal results of phase I/II studies of IL 13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant gliomaProceedings of the American Society of Clinical Oncology MeetingOrlando, USA2005 Abstract 1506
   Google Scholar
• KunwarSWestphalMMedhornMResults from PRECISE: a randomized phase 3 study in patients with first recurrent glioblastoma multiformed (GBM) comparing cintredekin besudotox (CB) administered via convection-enhanced delivery (CED) with Gliadel wafers (GW)Neuro Oncol200794467602 Abstract MA-61
   Web of Science ®Google Scholar